Shares of Bayer have quietly begun to rebound after nearly a decade of steady decline, much of it tied to the legal and financial fallout from the Monsanto acquisition. With tens of thousands of Roundup-related lawsuits still pending, the overhang remains significant, but recent developments may be signaling a shift in sentiment. Technically, the stock is showing signs of strength for the first time in years, with improving relative performance and new positioning in key index rankings. While legal uncertainties persist, might the market be starting to price in the possibility of resolution?